To estimate the prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) and to evaluate the associations between thyroid parameters, MAFLD and liver brosis in euthyroid patients with newly diagnosed type 2 diabetes mellitus (T2DM).
MethodsOverall, 689 patients with newly diagnosed T2DM and 110 subjects without diabetes were included. All the participants were euthyroid, and were categorized as non-MAFLD and MAFLD. Demographic information, biochemical parameters, and serum thyroid hormones were collected. The thyroid hormone sensitivity indices were calculated. MAFLD was de ned according to abdominal ultrasound and clinical manifestations. Noninvasive brosis indices were calculated to identify advanced liver brosis.
ResultsThe prevalence of MAFLD was signi cantly higher in patients with T2DM than in subjects without diabetes.Levels of free triiodothyronine (FT3) and FT3 to free thyroxine (FT4) ratio were signi cantly higher in subjects with MAFLD. In patients with T2DM, levels of thyroid stimulating hormone (TSH), Thyroid feedback quantilebased index (TFQI FT3 ) calculated using FT3 and TSH, thyrotroph T3 resistance index (TT3RI) and thyrotroph T4 resistance index (TT4RI) were signi cantly higher in subjects with MAFLD. The prevalence of MAFLD increased with the rise of FT3, FT3/FT4, TSH, and sensitivity to thyroid hormone indices (TFQI FT3 , TT3RI, and TT4RI).Positive correlations were signi cant between FT3, TFQI FT3 and MAFLD. But after further adjusted for BMI and HOMA-IR, the correlations were not signi cant. The incidence of advanced brosis tended to increase as the rise of TSH and sensitivity to thyroid hormone indices (TFQI FT3 , TT3RI, and TT4RI).
ConclusionMAFLD was prevalent in euthyroid patients with newly diagnosed T2DM. Higher normal FT3, TSH and impaired sensitivity to thyroid hormones are associated with increased risk of MAFLD.